Tirzepatide

Tirzepatide delivers clinically meaningful weight loss and glycemic improvement for adults with obesity or type 2 diabetes, but the benefits depend on ongoing weekly injections. The evidence shows average reductions of 15-20% body weight and HbA1c drops of 1-1.5% in trial populations, with the strongest signals in people whose BMI exceeds 35 kg/m2 or who have prediabetes Jastreboff 2025. Systematic reviews confirm that tirzepatide outperforms placebo and most comparators across diverse cohorts, while gastrointestinal upset remains the most common adverse event Cerchi 2025. Durability wanes after discontinuation, so candidates should be prepared for a long-term treatment plan integrated with diet, resistance training, and regular metabolic monitoring. Individuals without significant metabolic dysfunction, who seek short-term cosmetic change, or who cannot tolerate chronic injection regimens are less likely to achieve a favorable risk-benefit balance.

✅ Best for: Adults with BMI >=35 where time-to-effect matters and obesity complications are progressing despite serious lifestyle effort. Type 2 diabetics with poor glycemic control despite standard care. Adults with obesity and prediabetes where diabetes prevention is a primary goal, supported by Jastreboff 2025. HFpEF with obesity under cardiology supervision, supported by Packer 2025. Adults with obesity-related OSA using tirzepatide as adjunctive chronic disease care, not as a reason to abandon PAP without retesting. People who have accepted the long-term therapy model and paired the drug with resistance training, high protein, creatine, and body-composition monitoring.

❌ Avoid if: You have a personal or family history of medullary thyroid carcinoma or MEN2; are pregnant, trying to conceive, or unwilling to plan washout; have prior pancreatitis or severe gastric motility disease without specialist oversight; use oral contraceptives without discussing non-oral backup; have type 1 diabetes or use insulin / sulfonylureas without clinician dose adjustment; are over 60 with sarcopenia or osteoporosis risk and no plan to monitor muscle and bone; want a short-term detox, reset, or cosmetic cut; or are sourcing from gray-market research peptide sellers instead of regulated prescription channels. For people with 15-30 pounds to lose and no serious metabolic disease, the lifetime-drug model usually fails the risk-benefit test.